NCT02063724View on ClinicalTrials.gov

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2022

Conditions
Breast Cancer
Interventions
BIOLOGICAL

HER-2 pulsed Dendritic Cell Vaccine

6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.

Trial Locations (2)

19104

Hospital of the University of Pennsylvania, Philadelphia

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

Abramson Cancer Center at Penn Medicine

OTHER

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT02063724 - HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer | Biotech Hunter | Biotech Hunter